<DOC>
	<DOC>NCT00896831</DOC>
	<brief_summary>The study aimed to assess the effectiveness and safety of L-ornithine-L-aspartate in the management of hepatic encephalopathy.</brief_summary>
	<brief_title>Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy</brief_title>
	<detailed_description>Hepatic encephalopathy continues to be a major clinical problem in cirrhosis. Patients with minimal hepatic encephalopathy are at risk for accidents, had a decline in work performance, or complain of cognitive symptoms, with poor health-related quality of life. This study will compare L-ornithine-L-aspartate with placebo for 60 days to assess the effectiveness, safety and health-related quality of life of this drug.</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>Cirrhosis and diagnosis of minimal hepatic encephalopathy using psychometric tests and critical flicker frequency Hepatic encephalopathy grade 1 to 4 Use of drugs to treatment of hepatic encephalopathy (lactulose, neomycin) Psychoactive substance use within 72 hours</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>minimal hepatic encephalopathy</keyword>
	<keyword>L-ornithine-L-aspartate</keyword>
	<keyword>psychometric test</keyword>
	<keyword>critical flicker frequency</keyword>
	<keyword>quality of life</keyword>
	<keyword>Treatment</keyword>
	<keyword>Health-related quality of life</keyword>
</DOC>